Search research articles
Contact Us
Filters
Showing results (41-50 of 86) with videos related to
Page
of 9
Sort By:
Clinical Pharmacology and Therapeutics
|
February 14, 2022
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma
Ken Ogasawara, James Lymp, Timothy Mack, et al.
Nuclear Medicine and Biology
|
May 15, 2003
Aminocarboxylate complexes and octreotide complexes with no carrier added 177Lu, 166Ho and 149Pm
Wen Ping Li, C Jeff Smith, Cathy S Cutler, et al.
Molecular Plant
|
April 12, 2015
Transient Expression of Virally Delivered Meganuclease In Planta Generates Inherited Genomic Deletions
Arik Honig, Ira Marton, Michal Rosenthal, et al.
Cephalalgia : an International Journal of Headache
|
June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
David W Dodick, Richard B Lipton, Stephen Silberstein, et al.
Clinical Therapeutics
|
April 5, 2021
Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265]
Timothy R Smith, Marina Janelidze, George Chakhava, et al.
Clinical Therapeutics
|
November 30, 2020
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Timothy R Smith, Marina Janelidze, George Chakhava, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Dhamidhu Eratne, Jeff Smith, Kruti Patel, et al.
Biotechnology Journal
|
June 1, 2012
Crosstalk between endogenous and synthetic components--synthetic signaling meets endogenous components
Kevin J Morey, Mauricio S Antunes, Matt J Barrow, et al.
Cephalalgia : an International Journal of Headache
|
February 21, 2020
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina, Joel Saper, Roger Cady, et al.
British Journal of Haematology
|
November 21, 2022
Management of secondary central nervous system lymphoma
Kate Cwynarski, Thomas Cummin, Wendy Osborne, et al.
Page
of 9
Search research articles
Search
Showing results (41-50 of 86) with videos related to
Sort By:
Page
of 9
Clinical Pharmacology and Therapeutics
|
February 14, 2022
In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma
Ken Ogasawara, James Lymp, Timothy Mack, et al.
Nuclear Medicine and Biology
|
May 15, 2003
Aminocarboxylate complexes and octreotide complexes with no carrier added 177Lu, 166Ho and 149Pm
Wen Ping Li, C Jeff Smith, Cathy S Cutler, et al.
Molecular Plant
|
April 12, 2015
Transient Expression of Virally Delivered Meganuclease In Planta Generates Inherited Genomic Deletions
Arik Honig, Ira Marton, Michal Rosenthal, et al.
Cephalalgia : an International Journal of Headache
|
June 26, 2019
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
David W Dodick, Richard B Lipton, Stephen Silberstein, et al.
Clinical Therapeutics
|
April 5, 2021
Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265]
Timothy R Smith, Marina Janelidze, George Chakhava, et al.
Clinical Therapeutics
|
November 30, 2020
Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study
Timothy R Smith, Marina Janelidze, George Chakhava, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 25, 2025
Biomarkers
Dhamidhu Eratne, Jeff Smith, Kruti Patel, et al.
Biotechnology Journal
|
June 1, 2012
Crosstalk between endogenous and synthetic components--synthetic signaling meets endogenous components
Kevin J Morey, Mauricio S Antunes, Matt J Barrow, et al.
Cephalalgia : an International Journal of Headache
|
February 21, 2020
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
Messoud Ashina, Joel Saper, Roger Cady, et al.
British Journal of Haematology
|
November 21, 2022
Management of secondary central nervous system lymphoma
Kate Cwynarski, Thomas Cummin, Wendy Osborne, et al.
Page
of 9